Joshua Reed
2021 - Aldeyra Therapeutics
In 2021, Joshua Reed earned a total compensation of $1.8M as Chief Financial Officer at Aldeyra Therapeutics, a 9% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $172,857 |
|---|---|
| Option Awards | $1,231,734 |
| Salary | $432,143 |
| Other | $11,400 |
| Total | $1,848,134 |
Reed received $1.2M in option awards, accounting for 67% of the total pay in 2021.
Reed also received $172.9K in non-equity incentive plan, $432.1K in salary and $11.4K in other compensation.
Rankings
In 2021, Joshua Reed's compensation ranked 6,353rd out of 12,415 executives tracked by ExecPay. In other words, Reed earned more than 48.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,353 out of 12,415 | 49th |
Division Manufacturing | 2,708 out of 5,505 | 51st |
Major group Chemicals And Allied Products | 1,190 out of 2,375 | 50th |
Industry group Drugs | 1,059 out of 2,096 | 50th |
Industry Pharmaceutical Preparations | 767 out of 1,546 | 50th |
Source: SEC filing on April 25, 2022.
Reed's colleagues
We found two more compensation records of executives who worked with Joshua Reed at Aldeyra Therapeutics in 2021.